Compare Amphastar Pharmaceuticals Inc (AMPH) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Kinross Gold Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.48 (market cap $826.08M), while Kinross Gold Corporation trades at $23.32 (market cap $28.72B). The key difference: Kinross Gold Corporation is far larger — about 34.8× Amphastar Pharmaceuticals Inc's market cap, and Kinross Gold Corporation pays a 0.6% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KGC | |
|---|---|---|
Market Cap | $826.08M | $28.72B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $38.06 |
52-Week Low | $16.87 | $15.33 |
Enterprise Value | $1.22B | $27.28B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
KGC trades at $24.14, down 0.25% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals, with revenue growing from $3.5B in 2022 to $7.05B in 2025 and net income surging to $2.39B. Valuation ratios are attractive, including a P/E of 10.27 and EV/EBITDA of 5.3. Recent earnings have consistently beaten expectations, and a dividend of $0.04 per share was declared for H1-26.
The outlook is positive due to robust cash flow growth, a healthy balance sheet, and analyst consensus favoring a buy rating with a $36.25 price target. Key risks include potential margin pressure from rising costs and broader market volatility affecting gold prices. The stock presents a value opportunity if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
